Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm

被引：0
|
作者：
Becker, Pamela S. [1 ]
Medeiros, Bruno C. [2 ]
Stein, Anthony Selwyn [3 ]
Appelbaum, Frederick R. [4 ]
Scott, Bart L. [5 ]
Delaney, Colleen [5 ,6 ]
Othus, Megan
Hendrie, Paul C.
Gardner, Kelda M. [5 ]
Petersdorf, Stephen [7 ]
Pagel, John M.
Walter, Roland B. [5 ]
Parks, Cynthia [1 ]
Estey, Elihu H. [5 ]
机构：
[1] Univ Washington, Div Hematol, Seattle, WA 98195 USA
[2] Stanford Comprehens Canc Ctr, Div Hematol, Stanford, CA USA
[3] City Hope Natl Med Ctr, Hematol & HCT, Duarte, CA USA
[4] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA
[5] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[6] UW, Dept Pediat, Seattle, WA USA
[7] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.3594.3594
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3594
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Tipifarnib in combination with idarubicin and cytarabine in patients with newly diagnosed acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS).
    Ravandi-Kashani, F.
    Kantarjian, H.
    Garcia-Manero, G.
    O'Brien, S.
    Verstovsek, S.
    Estrov, Z.
    Faderl, S.
    Giles, F.
    Wright, J.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 351S - 351S
  • [32] HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants
    Xie, Mixue
    Jiang, Qi
    Li, Li
    Zhu, Jingjing
    Zhu, Lixia
    Zhou, De
    Zheng, Yanlong
    Yang, Xiudi
    Zhu, Mingyu
    Sun, Jianai
    Xie, Wanzhuo
    Ye, Xiujin
    PLOS ONE, 2016, 11 (10):
  • [33] Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
    Anwar, Asma
    Halpern, Anna B.
    Othus, Megan
    Scott, Bart L.
    Hendrie, Paul C.
    Becker, Pamela S.
    Perdue, Andrea M.
    Smith, Heather A.
    Chen, Tara L.
    Buckley, Sarah A.
    Orlowski, Kaysey F.
    Powell, Morgan A.
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD, 2015, 126 (23)
  • [34] Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome
    Wu, Lingyun
    Li, Xiao
    Su, Jiying
    Chang, Chunkang
    He, Qi
    Zhang, Xi
    Xu, Li
    Song, Luxi
    Pu, Quan
    LEUKEMIA & LYMPHOMA, 2009, 50 (09) : 1461 - 1467
  • [35] A phase Ⅳ study of homoharringtonine, cytarabine, aclacinomycin and G-CSF(HCAG) regimen compared with traditional IA regimen in the treatment of newly diagnosed elderly acute myeloid leukemia patients
    刘钊
    张赟翔
    王丽宁
    XIA Zheng
    MAO Yuan-fei
    ZHAO Hui-jin
    YOU Jian-hua
    YU Yang
    ZHAO Yu-bing
    REN Yu-hong
    LI Ya
    WANG Yan
    CHEN Qiu-sheng
    李军民
    陈瑜
    上海交通大学学报(医学版), 2017, 37 (08) : 1100 - 1105
  • [36] Results of a Phase 2, Open-Label Study of Idarubicin, Cytarabine, and Nivolumab in Patients With Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 9 - 11
  • [37] Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms
    Halpern, Anna B.
    Othus, Megan
    Huebner, Emily M.
    Scott, Bart L.
    Hendrie, Paul C.
    Percival, Mary-Elizabeth M.
    Becker, Pamela S.
    Smith, Heather A.
    Oehler, Vivian G.
    Orozco, Johnnie J.
    Cassaday, Ryan D.
    Gardner, Kelda M.
    Chen, Tara L.
    Buckley, Sarah A.
    Orlowski, Kaysey F.
    Anwar, Asma
    Estey, Elihu H.
    Walter, Roland B.
    HAEMATOLOGICA, 2019, 104 (04) : E143 - E146
  • [38] Homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF administered in patients with advanced myelodysplastic syndromes and relapsed or refractory acute myeloid leukemia
    Xu, Caigang
    Xu, Juan
    Liu, Ting
    Xiang, Bing
    Chang, Hong
    He, Chuan
    BLOOD, 2007, 110 (11) : 438A - 439A
  • [39] Clofarabine plus cytarabine (ARA-C) combination is active in newly diagnosed patients (pts) ≥ age 50 with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Faderl, S
    Gandhi, V
    Verstovsek, S
    Cortes, J
    Ravandi-Kashani, F
    Beran, M
    Garcia-Manero, G
    Koller, C
    O'Brien, S
    Ferrajoli, A
    Estrov, Z
    Kwari, M
    Plunkett, W
    Kantarjian, HM
    BLOOD, 2004, 104 (11) : 250A - 250A
  • [40] Limited phase I trial of sequential high dose cytarabine and clofarabine (HiDAC→CLOF) in relapsed or refractory acute myeloid leukemia.
    Powell, Bayard L.
    Lovato, James
    Kimbrough, Claire
    Lyerly, Susan
    Galloway-Daniels, Sonya
    Motley, Cathy
    Harrelson, Robin
    Keung, Yi Kong
    Thakuri, Mohan C.
    Molnar, Istvan
    Levitan, Denise
    Hurd, David Duane
    BLOOD, 2006, 108 (11) : 221B - 221B
12345